Ocrevus Delay As CHMP Continues Assessment?

The CHMP's assessment of Roche's novel multiple sclerosis therapy Ocrevus continues, making a year-end approval unlikely.

Question mark
When will Roche's Ocrevus get European approval? • Source: Shuitterstock

Roche's hopes of gaining EU approval for its new multiple sclerosis therapy, Ocrevus (ocrelizumab), before the end of the year are looking weak after the product failed to receive a positive opinion at the latest meeting of the CHMP last week.

Ocrevus, which was the first MS drug to get a label that included its use in primary progressive disease, has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip